Electrical stimulator
Hangzhou, Zhejiang, 311100, China
NCT Number: NCT07451158
Multicenter, double-blind, and randomized controlled trial of Ultra-Distal Transcutaneous Electrical Nerve Stimulation (TENS) Device for Migraine treatment.
This study is active but is not currently recruiting participants.
18 year–75 year
All sexes
Interventional
Not applicable
Hangzhou, Zhejiang, 311100, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
When subjects report experiencing or impending headache episodes, complete the VAS assessment and immediately administer transcutaneous electrical stimulation (TENS) therapy in the treatment area. Prior to activating the TENS wristband, first initiate EEG recording and maintain 5 minutes of rest. Subsequently, activate the TENS wristband for neuromodulation therapy while continuing rest and recording. After headache subsides, repeat the VAS assessment and maintain rest for 5 minutes before concluding. A safety follow-up (telephone consultation or online questionnaire) should be completed one week after the treatment session.
When subjects experience or anticipate headache onset, complete the VAS assessment and immediately administer transcutaneous electrical stimulation (TENS) in a non-treatment area. Before activating the TENS wristband, first initiate EEG recording and maintain 5 minutes of rest. Then activate the TENS wristband for neuromodulation therapy while continuing rest and recording. After headache subsides, repeat the VAS assessment and maintain rest for 5 minutes before concluding. Complete a safety follow-up one week after the same-day treatment (via telephone consultation or online questionnaire).
Time frame: Baseline and 2 hours post-treatment
After treatment, participants rated their headache intensity as 0 (no pain =0 points, mild =1 point, moderate =2 points, severe =3 points).
Time frame: Baseline and 2 hours post-treatment
Participants no longer experienced the pre-selected accompanying symptoms (e.g., nausea, vomiting, photophobia, phonophobia) after 2 hours of treatment.
Time frame: Baseline and 2 hours post-treatment
Pain relief measured by Visual Analogue Scale (VAS):Number of participants transitioning from moderate to mild pain at 2 hours post-treatment.
Time frame: Baseline and 2 hours post-treatment
Number of participants who resumed normal daily activities (e.g., ability to ambulate freely or return to work/school) by 2 hours post-treatment.
Time frame: Baseline and 24 hours post-treatment
Use of acute treatment drugs within 24 hours of treatment
Time frame: Baseline and 2-24 hours post-treatment
No recurrence of migraine attack occurred within 2-24 hours after treatment
Time frame: Baseline and 2-48 hours post-treatment
No recurrence of migraine attack occurred within 2-48 hours after treatment
Time frame: Baseline and 15,30,45,60, and 90 minutes post-treatment
Participants achieved pain-free status (VAS score 0) at 15,30,45,60, and 90 minutes post-treatment, having progressed from moderate to severe pain.
Time frame: Baseline and 15,30,45,60, and 90 minutes post-treatment
Participants' accompanying symptoms (e.g., nausea, vomiting, photophobia, phonophobia) did not reappear at 15,30,45,60, and 90 minutes after treatment
Second Affiliated Hospital, School of Medicine, Zhejiang University
Other
Multicenter, Double-blind, and Randomized Controlled Trial of Ultra-Distal Transcutaneous Electrical Nerve Stimulation (TENS) Device for Migraine Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06616194
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05576467
Behavior, Behavioral Symptoms
The Bronx, New York, United States
View Trial DetailsNCT06417775
Brain Diseases, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT03836040
Brain Diseases, Central Nervous System Diseases
San Diego, California, United States
View Trial Details